A share price of Cardiff Oncology Inc [CRDF] is currently trading at $2.07, up 1.47%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CRDF shares have gain 2.99% over the last week, with a monthly amount drifted -6.33%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cardiff Oncology Inc [NASDAQ: CRDF] stock has seen the most recent analyst activity on July 08, 2025, when Ladenburg Thalmann initiated its Buy rating and assigned the stock a price target of $19. Previously, Jefferies started tracking the stock with Hold rating on June 24, 2025, and set its price target to $3.50. On September 06, 2024, Craig Hallum initiated with a Buy rating and assigned a price target of $8 on the stock. William Blair started tracking the stock assigning a Outperform rating. Robert W. Baird initiated its recommendation with a Outperform and recommended $19 as its price target on December 08, 2021. In a note dated October 22, 2020, H.C. Wainwright initiated an Buy rating and provided a target price of $27 on this stock.
Cardiff Oncology Inc experienced fluctuations in its stock price throughout the past year between $1.90 and $5.64. Cardiff Oncology Inc [NASDAQ: CRDF] shares were valued at $2.07 at the most recent close of the market.
Analyzing the CRDF fundamentals
Trailing Twelve Months sales for Cardiff Oncology Inc [NASDAQ:CRDF] were 0.55M which represents -25.77% decline. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -99.51%, Pretax Profit Margin comes in at -93.46%, and Net Profit Margin reading is -93.45%. To continue investigating profitability, this company’s Return on Assets is posted at -0.67, Equity is -0.78 and Total Capital is -0.92. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.02 points at the first support level, and at 1.96 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.13, and for the 2nd resistance point, it is at 2.18.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cardiff Oncology Inc [NASDAQ:CRDF] is 4.42. As well, the Quick Ratio is 4.42, while the Cash Ratio is 0.65. Considering the valuation of this stock, the price to sales ratio is 250.37, the price to book ratio is 2.35.
Transactions by insiders
Recent insider trading involved PACE GARY W, Director, that happened on Jul 30 ’25 when 0.28 million shares were purchased. Director, PACE GARY W completed a deal on Jul 30 ’25 to buy 15000.0 shares. Meanwhile, Chief Financial Officer Levine James E. bought 2752.0 shares on Dec 17 ’24.
